EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial

Felipe Pereira, Joseph Magagnoli, Meenakshi Ambati, Talita Fernandes de Oliveira, Juliana Angélica Estevão de Oliveira, Vinicius Oliveira Pesquero, Lucas Zago Ribeiro, Dante Akira Kondo Kuroiwa, Fernando Korn Malerbi, Sergio Atala Dib, Nilva Bueno Moraes, Michel Eid Farah und 2 weitere

Med · 2025-09 · 6 (9) · 100747

DOI: 10.1016/j.medj.2025.100747 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Med, 2025-09. Verfasst von Felipe Pereira und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Oftalmologia e Ciências Visuais, Universidade Federal de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Lamivudine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NEI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Diabetic macular edema (DME) affects millions worldwide. Intraocular injections of expensive anti-vascular endothelial growth factor (VEGF) inhibitors associated with complications are standard therapy. Lamivudine, an inexpensive oral drug, inhibits inflammasome activation, which is implicated in DME. This randomized, double-blind, placebo-controlled trial compared oral lamivudine to placebo for improving visual acuity in center-involved DME (CI-DME). METHODS: Twenty-four adults enrolled between February 2022 and September 2023 with 1 or 2 eyes with CI-DME and a best-corrected visual acuity (BCVA) of less than 69 letters (Brazilian Registry of Clinical Trials RBR-87b6r5s) were randomized to lamivudine (150 mg twice daily; 10 participants; 16 eyes) or placebo (14 participants; 21 eyes) for 8 weeks. Participants were assigned intravitreous bevacizumab (1.25 mg) at week 4. Co-primary outcomes were mean changes in BCVA from baseline to weeks 4 and 8. Comparisons to anti-VEGF drugs used synthetic controls from DRCR.net Protocol T. Secondary outcomes included retinal thickness and adverse events. FINDINGS: At 4 weeks, BCVA improved 9.8 letters with lamivudine and decreased 1.8 letters with placebo (p < 0.001). At 8 weeks, BCVA improved 16.9 letters with lamivudine and bevacizumab and 5.3 letters with placebo and bevacizumab (p < 0.001). Lamivudine was associated with greater BCVA improvement than bevacizumab or ranibizumab (p < 0.05) and was not different from aflibercept (p = 0.5). There was no significant difference in retinal thickness or adverse events between groups. CONCLUSIONS: Lamivudine, an oral inflammasome inhibitor, significantly improved vision in patients with CI-DME. FUNDING: This work was supported by Universidade Federal de São Paulo, Latinofarma, UVA SIF, and NIH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyLamivudineHumansDouble-Blind MethodMaleFemaleMiddle AgedVisual AcuityAdministration, OralAgedAngiogenesis InhibitorsBevacizumabIntravitreal InjectionsTreatment OutcomeAdult

Stichwörter der Autor:innen

NRTITranslation to patientsclinical trialdiabetic macular edemainflammasomelamivudine

Substanzen

LamivudineAngiogenesis InhibitorsBevacizumab

Autor:innen und Institutionen

  • Departamento de Oftalmologia e Ciências Visuais, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Yale University, New Haven, CT, USA.
  • Departamento de Endocrinologia - Centro de Diabetes of Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Center for Advanced Vision Science and Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA; Department of Pathology, University of Virginia School of Medicine, Charlottesvill…

Förderung

  • NIA NIH HHS
  • NEI NIH HHS
  • National Institutes of Health
  • University of Virginia
  • Federal University of Sao Paulo

Zitieren

APA

Pereira, F., Magagnoli, J., Ambati, M., Fernandes de Oliveira, T., Estevão de Oliveira, J. A., Pesquero, V. O., Ribeiro, L. Z., Kondo Kuroiwa, D. A., Malerbi, F. K., Dib, S. A., Moraes, N. B., Farah, M. E., Rodrigues, E. B., & Ambati, J. (2025). Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial. Med, 6(9), 100747. https://doi.org/10.1016/j.medj.2025.100747

Vancouver

Pereira F, Magagnoli J, Ambati M, Fernandes de Oliveira T, Estevão de Oliveira JA, Pesquero VO, et al. Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial. Med. 2025;6(9):100747. doi:10.1016/j.medj.2025.100747

BibTeX
@article{Pereira2025,
  author = {Pereira, Felipe and Magagnoli, Joseph and Ambati, Meenakshi and Fernandes de Oliveira, Talita and Estevão de Oliveira, Juliana Angélica and Pesquero, Vinicius Oliveira and Ribeiro, Lucas Zago and Kondo Kuroiwa, Dante Akira and Malerbi, Fernando Korn and Dib, Sergio Atala and Moraes, Nilva Bueno and Farah, Michel Eid and Rodrigues, Eduardo Buchele and Ambati, Jayakrishna},
  title = {Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial},
  journal = {Med},
  year = {2025},
  volume = {6},
  number = {9},
  pages = {100747},
  doi = {10.1016/j.medj.2025.100747}
}
Kostenlos starten →